Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

September 26, 2023

Study Completion Date

September 26, 2023

Conditions
Advanced Nonhaematologic Malignancies
Interventions
DRUG

BOS172738

Oral capsules

Trial Locations (21)

19111

Fox Chase Cancer Center, Philadelphia

29010

Hospital Universitario Virgen de la Victoria, Málaga

77030

MD Anderson Cancer Center, Houston

Unknown

Institut Jules Bordet, Brussels

UZ Leuven, Leuven

Institut Bergonié, Bordeaux

Centre Léon Bérard, Lyon

Hôpital Pitié-Salpêtrière, Paris

Institut Gustave Roussy, Villejuif

Prince of Wales Hospital, Hong Kong

Chungbuk National University Hospital, Cheongju-si

Seoul National University Bundang Hospital, Gyeonggi-do

Asan Medical Center, Seoul

Korea University Anam Hospital, Seoul

Severance Hospital, Yonsei University College of Medicine, Seoul

Hospital Germans Trias i Pujol, Badalona

Instituto Oncológico Dr. Rosell, S.L., Barcelona

Start Madrid - Ciocc, Madrid

START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid

Taichung Veterans General Hospital, Taichung

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Boston Pharmaceuticals

INDUSTRY

NCT03780517 - Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors | Biotech Hunter | Biotech Hunter